Tags

Type your tag names separated by a space and hit enter

ColdZyme® protects airway epithelia from infection with BA.4/5.
Respir Res. 2022 Oct 31; 23(1):300.RR

Abstract

Vaccines against SARS-CoV-2 protect from critical or severe pathogenesis also against new variants of concern (VOCs) such as BA.4 and BA.5, but immediate interventions to avoid viral transmission and subsequent inflammatory reactions are needed. Here we applied the ColdZyme® medical device mouth spray to fully differentiated, polarized human epithelium cultured at an air-liquid interphase (ALI). We found using VOCs BA.1 and BA.4/5 that this device effectively blocked respiratory tissue infection. While infection with these VOCs resulted in intracellular complement activation, thus enhanced inflammation, and drop of transepithelial resistance, these phenomena were prevented by a single administration of this medical device. Thus, ColdZyme® mouth spray significantly shields epithelial integrity, hinders virus infection and blocks in a secondary effect intrinsic complement activation within airway cultures also in terms of the highly contagious VOCs BA.4/5. Crucially, our in vitro data suggest that ColdZyme® mouth spray may have an impact to protect against SARS-CoV-2 transmission, also in case of the Omicron BA.1, BA.4 and BA.5 variants.

Links

PMC Free PDF

Authors+Show Affiliations

Zaderer V
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstrasse 41/R311, 6020, Innsbruck, Austria.
Dichtl S
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstrasse 41/R311, 6020, Innsbruck, Austria.
Bellmann Weiler R
Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Lass Flörl C
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstrasse 41/R311, 6020, Innsbruck, Austria.
Posch W
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstrasse 41/R311, 6020, Innsbruck, Austria. wilfried.posch@i-med.ac.at.
Wilflingseder D
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstrasse 41/R311, 6020, Innsbruck, Austria. doris.wilflingseder@i-med.ac.at.

MeSH

HumansEpithelial CellsCOVID-19 VaccinesSARS-CoV-2COVID-19EpitheliumRespiratory Tract Infections

Pub Type(s)

Letter

Language

eng

PubMed ID

36316674

Citation

Zaderer, Viktoria, et al. "ColdZyme® Protects Airway Epithelia From Infection With BA.4/5." Respiratory Research, vol. 23, no. 1, 2022, p. 300.
Zaderer V, Dichtl S, Bellmann Weiler R, et al. ColdZyme® protects airway epithelia from infection with BA.4/5. Respir Res. 2022;23(1):300.
Zaderer, V., Dichtl, S., Bellmann Weiler, R., Lass Flörl, C., Posch, W., & Wilflingseder, D. (2022). ColdZyme® protects airway epithelia from infection with BA.4/5. Respiratory Research, 23(1), 300. https://doi.org/10.1186/s12931-022-02223-2
Zaderer V, et al. ColdZyme® Protects Airway Epithelia From Infection With BA.4/5. Respir Res. 2022 Oct 31;23(1):300. PubMed PMID: 36316674.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - ColdZyme® protects airway epithelia from infection with BA.4/5. AU - Zaderer,Viktoria, AU - Dichtl,Stefanie, AU - Bellmann Weiler,Rosa, AU - Lass Flörl,Cornelia, AU - Posch,Wilfried, AU - Wilflingseder,Doris, Y1 - 2022/10/31/ PY - 2022/08/23/received PY - 2022/10/05/accepted PY - 2022/11/1/entrez PY - 2022/11/2/pubmed PY - 2022/11/3/medline KW - BA.4 KW - BA.5 KW - Prophylaxis KW - SARS-CoV-2 KW - Transmission KW - Variants of concern SP - 300 EP - 300 JF - Respiratory research JO - Respir Res VL - 23 IS - 1 N2 - Vaccines against SARS-CoV-2 protect from critical or severe pathogenesis also against new variants of concern (VOCs) such as BA.4 and BA.5, but immediate interventions to avoid viral transmission and subsequent inflammatory reactions are needed. Here we applied the ColdZyme® medical device mouth spray to fully differentiated, polarized human epithelium cultured at an air-liquid interphase (ALI). We found using VOCs BA.1 and BA.4/5 that this device effectively blocked respiratory tissue infection. While infection with these VOCs resulted in intracellular complement activation, thus enhanced inflammation, and drop of transepithelial resistance, these phenomena were prevented by a single administration of this medical device. Thus, ColdZyme® mouth spray significantly shields epithelial integrity, hinders virus infection and blocks in a secondary effect intrinsic complement activation within airway cultures also in terms of the highly contagious VOCs BA.4/5. Crucially, our in vitro data suggest that ColdZyme® mouth spray may have an impact to protect against SARS-CoV-2 transmission, also in case of the Omicron BA.1, BA.4 and BA.5 variants. SN - 1465-993X UR - https://www.unboundmedicine.com/medline/citation/36316674/ColdZyme®_protects_airway_epithelia_from_infection_with_BA_4/5_ DB - PRIME DP - Unbound Medicine ER -